Lectures 6 Cardiac, 7 Vascular, 8 Immunity, 9 Pulmonary and 10 Blood Disorders, condensed. ★ = the lecturer said to know it. Mechanism only, never management.
| Term | What you need to know |
|---|---|
| Coronary heart disease | Insufficient delivery of oxygenated blood to the myocardium because of ATHEROSCLEROTIC coronary arteries. About 50% of cardiovascular deaths. Also called ischemic heart disease, coronary artery disease. |
| Ischemia = supply vs demand | Begins when oxygen SUPPLY < DEMAND → less ATP (adenosine triphosphate). Causes abnormal function AND abnormal rhythms; prolonged → irreversible damage. |
| Supply falls | Large plaques · acute platelet aggregation then thrombosis · VASOSPASM · abnormal microcirculation · poor perfusion pressure. |
| Demand rises | Workload = HEART RATE · PRELOAD · AFTERLOAD · CONTRACTILITY. Raise any one → more oxygen demand. |
| Etiologies | ATHEROSCLEROSIS behind almost all → predisposes to thrombosis, vasospasm, endothelial dysfunction. Microcirculation: small-vessel endothelium regulates flow abnormally. Uncommon: low blood oxygen content (respiratory); poor perfusion (hypotension, hypovolemia). |
| Major risk factors | Age · family history · abnormal lipids · smoking · hypertension · diabetes mellitus · obesity. |
| Probable risk factors | Male sex · HOMOCYSTEINE · high-sensitivity C-reactive protein. |
| Collateral circulation | Develops when plaque builds over YEARS — why slow occlusion is tolerated better than sudden. |
| Flow tracks demand | Myocardial oxygen consumption and blood flow correspond NEARLY LINEARLY; METABOLIC SIGNALS are the principal determinants of delivery. |
| Coronary anatomy | LEFT MAIN → left anterior descending (anterior interventricular) + CIRCUMFLEX. RIGHT CORONARY → marginal + posterior interventricular. |
| Frank–Starling | More diastolic filling → more ejected. Force ∝ initial sarcomere length (preload). Maximal force at 2.6 micrometers, rarely exceeded in the normal heart. |
| Term | What you need to know |
|---|---|
| Low-density lipoprotein | Cholesterol-rich → HIGHEST risk. |
| Very-low-density lipoprotein | Triglyceride-rich → INCREASES risk. |
| High-density lipoprotein | DECREASES risk — carries cholesterol BACK TO THE LIVER, away from plaque. |
| Familial hypercholesterolemia | Common single-gene hyperlipidemia (classically taught as the most common). Defective LOW-DENSITY LIPOPROTEIN RECEPTOR on liver cells → liver cannot clear cholesterol. |
| Homocysteine | Amino acid from METHIONINE → CYSTEINE. Atherogenic + prothrombotic: intimal thickening, elastic lamina disruption, smooth muscle hypertrophy, platelet accumulation, platelet-rich occlusive thrombus. |
| Plaque sequence | ENDOTHELIAL INJURY (wall stress, toxins, inflammation, hyperlipidemia) → permeable endothelium, leukocytes recruited → low-density lipoprotein leaks in and is OXIDIZED → FOAM CELLS → mediators + growth factor → smooth muscle proliferation → LIPID CORE → collagen/fibrin CAP. |
| 75% | Occlusion at which blood flow is COMPROMISED. |
| Vulnerable plaque (slide 24, image only) | LARGE lipid core · THIN fibrous cap · rich in MACROPHAGES · increased MMPs (matrix metalloproteinases) · POOR in smooth muscle · LOW-GRADE stenosis. |
| Stable vs vulnerable | Stable: thick cap, small core, many smooth muscle cells. Vulnerable: thin cap, large core, many macrophages. Smooth muscle BUILDS the cap; macrophages DIGEST it. |
| Why plaques rupture | Composition + mechanical stress. Trigger: SHEAR from high-velocity flow through a severe stenosis. VASA VASORUM capillaries hemorrhage → pressure builds inside the plaque. |
| Rupture consequences | Exposed subendothelial proteins → platelet aggregation → THROMBUS; EMBOLI block smaller vessels downstream. |
| Term | What you need to know |
|---|---|
| Coronary syndromes | CHRONIC: stable angina, ischemic cardiomyopathy. ACUTE: unstable angina, myocardial infarction. Classified by severity and onset. |
| Angina pectoris | Intermittent ischemia NOT enough to kill cells; when demand rises; may cause pulmonary congestion. |
| Stable (typical) | MOST COMMON. Fixed stenosis → ischemia only under increased WORKLOAD. |
| Prinzmetal (variant) | VASOSPASM (cause unknown). Unpredictable; typically at REST, not with exertion. |
| Unstable (crescendo) | May progress to acute ischemia → counted with the ACUTE coronary syndromes. |
| Acute coronary syndrome | Unstable angina + myocardial infarction (hard to tell apart clinically). Pain longer than typical angina; PLAQUE RUPTURE + ACUTE THROMBOSIS. |
| Infarction mechanism | Prolonged/total loss of flow → NECROSIS or APOPTOSIS. Thrombus on a cracked plaque → platelet plug → clotting cascade → occlusion. Outcome depends on COLLATERALS, WORKLOAD, TIME. |
| Occlusion timeline | Immediately: ATP depleted. Few minutes: cannot contract. AFTER 30 MINUTES: irreversible necrosis. |
| Location | Nearly all in LEFT VENTRICLE. Left anterior descending 40–50% · right coronary 30–40% · left circumflex 15–20%. |
| Gross changes | First several hours: hard to see by eye (slide: 6 h) · 18–24 h: paler · then yellow, soft, red vascular border · 1–2 weeks: necrotic tissue removed · by 6 weeks: fibrous scar. |
| Term | What you need to know |
|---|---|
| Stenosis vs regurgitation | STENOSIS = fails to OPEN → PRESSURE work, gradient across valve. REGURGITATION = fails to CLOSE → VOLUME work. |
| Stenosis facts | Hemodynamics affected at 50% closure; slow → compensatory HYPERTROPHY. Causes: RHEUMATIC scarring, aging CALCIFICATION. |
| Regurgitation facts | Acute: infection or PAPILLARY MUSCLE RUPTURE. Important causes: rheumatic heart disease, infective endocarditis, degenerative valve changes, aortic root dilation. |
| Mitral stenosis | DIASTOLIC left atrial > left ventricular gradient. Left atrial congestion/pressure ↑, pulmonary pressure ↑, stroke volume ↓ → pulmonary hypertension → right heart failure. Late: ATRIAL FIBRILLATION, atrial enlargement, ATRIAL CLOTS. |
| Mitral regurgitation | SYSTOLIC backflow into atrium. HIGH AFTERLOAD INCREASES it. Atrium AND ventricle dilate + hypertrophy; severe → left heart failure. |
| Mitral valve prolapse | BALLOONING into left atrium in systole. Usually silent; sometimes some regurgitation. |
| Aortic stenosis | Most often AGE-RELATED CALCIFICATION; common with BICUSPID valve (slide: clinically apparent over 79). Systolic left ventricle–aortic gradient → LEFT VENTRICULAR HYPERTROPHY → ischemia and ANGINA → failure. |
| Aortic regurgitation | DIASTOLIC leak back into left ventricle. AORTIC ROOT DILATION common (aging, connective tissue disease). Left ventricle hypertrophies + dilates; AORTIC DIASTOLIC PRESSURE FALLS (blood leaks back). |
| Timing rule | DIASTOLE: mitral stenosis, aortic regurgitation. SYSTOLE: mitral regurgitation, prolapse, aortic stenosis. |
| Term | What you need to know |
|---|---|
| Rheumatic heart disease | After GROUP A BETA-HEMOLYTIC STREPTOCOCCUS. IMMUNE attack by CROSS-REACTIVITY; HLA (human leukocyte antigen) predisposition. All layers → carditis. Valves: swelling, erosions, platelets + fibrin, then SCARRING and SHORTENING. |
| Infective endocarditis | Invasion + colonization of endocardium; BLOODSTREAM INVASION is a prerequisite. VEGETATIONS = organisms in FIBRIN → dysfunction + EMBOLI. Commonest: Streptococcus, Staphylococcus aureus. |
| Subacute endocarditis | Insidious; needs a PREEXISTING valve lesion. LESS VIRULENT organisms (typically Streptococcus) cannot attack a healthy endocardium. S. aureus is ACUTE, not subacute (the slide lists it here; Robbins pairs it with the acute form). |
| Myocarditis | Inflammation + leukocyte infiltration + necrosis. Microbes (most often viruses, classically COXSACKIEVIRUS), immune disease, physical agents. Left ventricular dysfunction, chambers sometimes dilated, edematous muscle, endocardium usually NORMAL. |
| Dilated cardiomyopathy | Also 'congested'. Dilation of one or both ventricles → failure. ALCOHOL · GENETICS · PREGNANCY · POST-VIRAL. |
| Hypertrophic cardiomyopathy | Thick, HYPERKINETIC muscle. OUTFLOW OBSTRUCTION + impaired DIASTOLIC FILLING. |
| Restrictive cardiomyopathy | Stiff, FIBROTIC, noncompliant (e.g. AMYLOIDOSIS) → restricted filling → low stroke volume → failure. |
| Pericardial effusion types | SEROUS transudate (heart failure, hypoproteinemia) · SEROSANGUINOUS (blunt trauma, heart surgery, cardiopulmonary resuscitation) · CHYLOUS (lymph obstruction) · BLOOD/hemopericardium (penetrating trauma). |
| Tamponade | Fluid, especially if it collects quickly, COMPRESSES chambers from outside → filling impaired. Life-threatening. |
| Pericarditis | ACUTE: mostly idiopathic, mostly VIRAL. CHRONIC: ADHESIVE mediastinopericarditis (heart stuck to mediastinum → workload ↑) or CONSTRICTIVE (dense scarred sac = STIFF CAGE → impaired diastolic filling). |
| Not in the deck | Objective m (blood pressure regulation) → see Lecture 7. Objective n (conduction system): no slide; only ischemia → abnormal rhythms, mitral stenosis → atrial fibrillation. |
| Term | What you need to know |
|---|---|
| Five components | ARTERIES high pressure, strong walls, fast flow → ARTERIOLES control release into capillaries (main resistance, 'small but mighty') → CAPILLARIES exchange → VENULES collect → VEINS return blood, RESERVOIR, low pressure, thin walls. |
| Three layers | INTIMA: endothelium on basement membrane + thin matrix. MEDIA: elastin + smooth muscle 'like tree rings', expand in systole, recoil in diastole. ADVENTITIA: loose connective tissue, nerves, its own small arterioles in large vessels. |
| Capillaries | NO MEDIA. ≈ red cell diameter. Large cross-section, LOW flow → easy exchange. Densest in MYOCARDIUM and BRAIN. Pericytes around them. |
| Capillary types | CONTINUOUS (least permeable; blood–brain barrier) · FENESTRATED (kidney glomeruli, small intestine) · SINUSOIDAL (leakiest; liver, marrow, spleen, endocrine). |
| Functions | Nutrients in · wastes out · hormones carried · HOMEOSTASIS of tissue fluid. |
| Loops | PULMONARY: right heart → lungs. SYSTEMIC: left heart → tissues → right heart. Artery = AWAY from heart, so pulmonary artery carries deoxygenated blood. |
| Veins hold | About 66% of total blood volume. |
| Term | What you need to know |
|---|---|
| Healthy endothelium | NONTHROMBOGENIC; modulates medial tone (resistance); METABOLIZES ANGIOTENSIN; regulates inflammation; controls smooth muscle growth. |
| Smooth muscle cells | Predominant media cell. Proliferate; make collagen, elastin, proteoglycans, growth factors, cytokines; constrict/dilate. |
| Neointimal hyperplasia | Injury → smooth muscle MIGRATES INTO INTIMA, proliferates, makes matrix; endothelium regrows with LESS NITRIC OXIDE; platelets activate; leukocytes recruited → thick intima, NARROW LUMEN. Same response to ANY injury. |
| The twofold problem | Thicker intima narrows the lumen AND lost nitric oxide (a vasodilator) lets it constrict. |
| Two mechanisms | NARROWING (progressive: atherosclerosis; precipitous: thrombosis, embolism) or WEAKENING (dilation, rupture). |
| Size tends to predict disease | Tendencies, not rules (atherosclerosis also affects the aorta). LARGE elastic (aorta 2–3.5 cm) → ANEURYSM (elastic loss). MEDIUM muscular (coronary 3–4 mm, renal) → ATHEROSCLEROSIS. SMALL (≤2 mm) + ARTERIOLES (20–100 micrometers) → HYPERTENSION. |
| Blood pressure | = CARDIAC OUTPUT × VASCULAR RESISTANCE. Resistance set at ARTERIOLES (constrictors vs dilators). Output = rate × stroke volume; volume set by SODIUM (water follows sodium). |
| Low pressure response | Kidney RENIN (low afferent arteriolar pressure) → angiotensinogen → ANGIOTENSIN I → endothelial catabolism → ANGIOTENSIN II → smooth muscle tone ↑ + ALDOSTERONE ↑ (sodium resorption). |
| Hypertension risks | Atherosclerosis, congestive heart failure, renal failure, CEREBRAL HEMORRHAGE, AORTIC DISSECTION. |
| Essential hypertension | 90–95%, idiopathic. Genetic + environmental. INSUFFICIENT RENAL SODIUM EXCRETION → volume ↑ → output ↑ → constriction → pressure ↑. |
| Secondary hypertension | RENOVASCULAR: renal artery stenosis → low afferent pressure → RENIN. PRIMARY HYPERALDOSTERONISM: a common cause. |
| Term | What you need to know |
|---|---|
| Arteriosclerosis | 'Hardening of the arteries': wall thickening + LOSS OF ELASTICITY. Four patterns below. |
| Arteriolosclerosis | Small arteries/arterioles; HYPERTENSION. HYALINE = protein-thickened glassy wall, narrow lumen. HYPERPLASTIC = ONION SKINNING (concentric smooth muscle). |
| Fibromuscular intimal hyperplasia | Muscular arteries; inflammation or mechanical injury; a healing response → IN-STENT RESTENOSIS; limits solid-organ transplants. |
| Mönckeberg medial sclerosis | CALCIFICATION OF THE MEDIA of muscular arteries; usually NOT clinically significant. |
| Atherosclerosis | 'Gruel' + 'hardening'. MOST clinically relevant. Coronary, cerebral, peripheral disease; slide: about half of Western deaths (an older figure; roughly a third of United States deaths today). |
| Risk factors | Hyperlipidemia · LIPOPROTEIN(a) (altered low-density lipoprotein, independent of total cholesterol) · smoking · hypertension · diabetes · METABOLIC SYNDROME · C-reactive protein · FAMILY HISTORY = strong risk, classically taught as the most important · age · men + postmenopausal women. |
| Sequence | Injury → LOW-DENSITY LIPOPROTEIN accumulates → MONOCYTE adhesion → PLATELET adhesion → smooth muscle RECRUITED → proliferation, matrix, T cells → lipid → CALCIFICATION. |
| Atheroma | Intimal plaque into the lumen: SOFT LIPID CORE + FIBROUS CAP. Stable → ischemia; unstable → rupture, thrombosis, embolism. |
| ★ Peripheral arterial disease | 'Do know': stenosis → ischemia → CLAUDICATION when working muscle's demand rises. |
| Term | What you need to know |
|---|---|
| Aneurysm vs dissection | ANEURYSM = localized abnormal DILATION. DISSECTION = blood enters a wall defect and TUNNELS through the MEDIA. |
| Shapes | TRUE saccular (focal bulge, 'berry') · TRUE fusiform (whole circumference) · FALSE (ruptured wall, hematoma held by extravascular tissue) · DISSECTION (intimal tear splits media). |
| Weakening ≠ rupture | An aneurysm is a WEAK wall, not a ruptured one; rupture risk rises with SIZE (in lecture: under 4 cm rarely, over 5.5 cm very high). |
| Pathogenesis | Poor connective tissue (defective collagen; abnormal transforming growth factor signaling = MARFAN) · collagen degradation > synthesis (inflammation, proteases) · smooth muscle LOSS (ischemia, hypertension, TERTIARY SYPHILIS). |
| Predisposing | Atherosclerosis · hypertension · smoking. |
| Abdominal aortic aneurysm | ATHEROSCLEROTIC; abdominal aorta + common iliac arteries. |
| Thoracic aortic aneurysm | HYPERTENSION; also Marfan, inflammation. |
| Aortic dissection | Laminar planes of MEDIA SPLIT → blood channel in the wall. HYPERTENSION = major risk factor. |
| Cerebral saccular (berry) | Thin/absent media; absent or fragmented internal elastic lamina. LACK OF ELASTIC LAMINA = main feature. Usually acquired. |
| Fusiform / mycotic | Fusiform: whole circumference (atherosclerosis). MYCOTIC: infected emboli from INFECTIVE ENDOCARDITIS (rare). |
| Term | What you need to know |
|---|---|
| Fibromuscular dysplasia | Focal irregular thickening (hyperplasia + fibrosis of MEDIA and INTIMA) of medium/large muscular arteries → stenosis. RENAL arteries. 'STRING OF BEADS' on angiography; may dilate and rupture. |
| Vasculitis | Vessel wall inflammation, mostly SMALL vessels. Mechanisms: IMMUNE-MEDIATED or DIRECT INFECTIOUS INVASION. Large: giant cell arteritis. Medium: polyarteritis nodosa, Kawasaki. Small: ANCA (anti-neutrophil cytoplasmic antibody) necrotizing; immune complex (lupus, rheumatoid arthritis). Said to go light. |
| Raynaud phenomenon | EXAGGERATED VASOCONSTRICTION to COLD + STRESS, extremities. WHITE (spasm) → BLUE (anoxia) → RED (oxygenated blood returns). |
| Arteriovenous fistula | Direct artery–vein link BYPASSING CAPILLARIES: developmental, aneurysm rupturing into a vein, penetrating injury, inflammatory necrosis, surgical (hemodialysis access). |
| Veins | Larger lumen, THINNER MEDIA (capacitance), VALVES stop gravitational backflow. |
| Varicose veins | Dilated, tortuous; VALVE INSUFFICIENCY; chronic high intraluminal pressure + weak wall. Superficial (saphenous), legs; also pelvis/rectum. |
| Esophageal varices / hemorrhoids | Varices: submucosal distal esophageal veins from CIRRHOSIS + PORTAL HYPERTENSION. Hemorrhoids: varicose venous plexus at the ANORECTAL junction. |
| Deep vein thrombosis | Deep veins (femoral, popliteal, tibial); STASIS in a dilated vein. THIRD most common cardiovascular cause of death. |
| Deep vein thrombosis risks | Reduced flow (IMMOBILITY) · raised venous pressure · mechanical injury · raised viscosity (dehydration, thrombocytosis) · anatomy · hypercoagulable (cancer, sepsis, lupus, ORAL ESTROGEN). |
| Virchow triad | VESSEL WALL DAMAGE · ABNORMAL BLOOD FLOW (turbulence or stasis) · HYPERCOAGULABILITY. |
| Clot fate | Neutrophils + macrophages infiltrate fibrin; COLLAGEN replaces fibrin over weeks → less flow. Dislodges → EMBOLUS → PULMONARY ARTERY = pulmonary embolus. |
| Term | What you need to know |
|---|---|
| Immunity: 3 functions | DEFENSE (resistance to invaders) · SURVEILLANCE (of self, for mutant or cancerous cells) · HOMEOSTASIS (removing cellular debris). |
| Memory & specificity | Memory = faster, stronger adaptive response on RE-EXPOSURE. B- and T-cell receptors recognize particular EPITOPES; innate receptors recognize patterns shared by groups of organisms. |
| Active vs passive | ACTIVE: the body's own response after antigen exposure (natural = met naturally; artificial = VACCINATION). PASSIVE: PREFORMED antibodies transferred; immediate protection that declines. |
| Passive examples | Natural: maternal IgG through the PLACENTA, IgA in BREAST MILK. Artificial: tetanus and rabies immune globulin. |
| Innate immunity | Acts WITHOUT prior sensitization: skin and mucosal barriers, phagocytes, complement, interferons. Natural killer cells ≈ 5–15% of circulating lymphocytes. |
| Granulocytes | NEUTROPHIL: phagocytosis, first responders, most numerous. EOSINOPHIL: allergy and parasites. BASOPHIL: like tissue mast cells (★ 'Baso B blood', mast cells in tissue). |
| Monocyte → macrophage | Monocytes enter tissues during inflammation and become macrophages (tissue macrophage = HISTIOCYTE); they remove material and coordinate inflammation. |
| Lymphocytes | B: humoral, matures in BONE MARROW, becomes the plasma cell. T: cellular, matures in the THYMUS (★ 'T cells, thymus'). Natural killer: needs NO specific antigen; kills tumor and infected cells. |
| Markers | T: CD3 (CD4 or CD8). B: CD19, CD20; surface immunoglobulin LOST as a plasma cell. Natural killer: CD56, CD16. |
| Phagocytosis | Adhere → pseudopods engulf (PHAGOSOME) → fuse with lysosome (PHAGOLYSOSOME) → acid hydrolases digest → residual body → EXOCYTOSIS. |
| Lymph flow | No pump: SKELETAL MUSCLE movement, THORACIC pressure changes in breathing, pulsing ARTERIES; valves keep it one-way. |
| Term | What you need to know |
|---|---|
| B cell → plasma cell | Antigen-INDEPENDENT phase: surface IgM. Antigen-DEPENDENT phase (started by antigen exposure): becomes a PLASMA CELL secreting specific antibody. Antigen SELECTS the matching B cell → clonal expansion → plasma + memory cells. |
| Primary response | After FIRST exposure; develops over days; IgM rises first; memory cells form. |
| Secondary response | After RE-EXPOSURE; memory cells → FASTER, STRONGER (★); class-switched antibody, often IgG, higher and longer. ★ High IgM = first exposure; low IgM + high IgG = earlier exposure. |
| Antibody unit | 2 HEAVY + 2 LIGHT chains (light = KAPPA or LAMBDA). Heavy + light VARIABLE regions = antigen-binding site. Heavy-chain CONSTANT region decides the CLASS. |
| Fab vs Fc | Fab = antigen-binding arms. Fc = constant stem → EFFECTOR functions (complement-binding site on CH2). Papain cuts IgG into 2 Fab + Fc. |
| IgM | 5–10%. PENTAMER (J chain) when secreted. Often FIRST in a new response; AGGLUTINATION; efficient classical complement. |
| IgG | 75–80%, the largest share. Monomer, 4 subclasses. CROSSES THE PLACENTA (★ how maternal immunity reaches the baby); prominent in secondary responses. |
| IgA · IgD · IgE | IgA 10–15%: secretory DIMER (saliva, tears, colostrum), blocks microbial attachment. IgD <1%: B-cell receptor with IgM. IgE <1%: on MAST CELLS and BASOPHILS → allergy, anaphylaxis, parasites. |
| Antibody functions | AGGLUTINATION (clumps cells) · NEUTRALIZATION (blocks without destroying ★) · LYSIS (with complement) · PRECIPITATION (cross-links soluble antigen) · OPSONIZATION (coats for phagocytes). |
| ABO | O red cells carry neither A nor B → O is the universal red-cell donor (★); AB recipients have neither antibody → take O, A, B, AB. |
| Term | What you need to know |
|---|---|
| ★ CD4 vs CD8 | 'Four letters in HELP': CD4 = HELPER, reads MHC (major histocompatibility complex) CLASS II. CD8 = CYTOTOXIC, reads CLASS I. |
| Helper T cell | COORDINATES cellular and humoral responses by cytokines and contact; supports B-cell antibody production; IFN-γ (interferon gamma) activates macrophages. |
| Cytotoxic T cell | Kills virus-infected, tumor and transplanted cells: PERFORIN + GRANZYMES → target-cell APOPTOSIS. |
| Regulatory T cell | LIMITS immune activation, maintains SELF-TOLERANCE; many are CD4 expressing FOXP3. |
| ADCC | Antibody-dependent cellular cytotoxicity: the natural killer cell's CD16 binds the Fc of IgG coating a target. |
| Hypersensitivity | Humoral or cellular immune reactions that INJURE the body. Numbered by MECHANISM, not severity (★). |
| Type I | IgE fixed on MAST CELLS/basophils after a sensitizing exposure; re-exposure → HISTAMINE release. Local allergy or ANAPHYLAXIS (bronchospasm, laryngeal edema, hypotension). |
| Type II | IgG or IgM binds antigen ON cells or tissue → phagocytosis, complement, ADCC; can STIMULATE or BLOCK receptors. ABO incompatibility, anti-glomerular basement membrane disease. |
| Type III | Antigen–antibody COMPLEXES deposit in tissue or vessel walls. Arthus (local), serum sickness (systemic), LUPUS. |
| Type IV | Sensitized CD4 or CD8 T CELLS; delayed 24–72 h; granulomas. Contact dermatitis, tuberculosis reactions, transplant rejection. |
| Term | What you need to know |
|---|---|
| Complement | Proteins made mostly by the LIVER, circulating as INACTIVE precursors; activation = a regulated CASCADE. |
| 3 pathways (★) | CLASSICAL: C1 binds antigen-bound IgM or IgG. LECTIN: mannose-binding lectin binds microbial carbohydrate. ALTERNATIVE: C3 on permissive surfaces (factor B, factor D, properdin). All CONVERGE ON C3. |
| 3 outcomes | OPSONIZATION (C3b coat) · INFLAMMATION (C3a, C4a, C5a: vasodilation, attraction of phagocytes) · MEMBRANE ATTACK COMPLEX (C5b + C6–C9 pore → lysis). ★ Lysis is only ONE outcome. |
| Autoimmunity (deck) | No slide of its own: regulatory T cells keep self-tolerance; anti-self antibody can destroy or stimulate/block (type II); lupus is type III; autoantibodies rise with age. |
| Primary immunodeficiency | INTRINSIC, often GENETIC. X-linked agammaglobulinemia: no B-cell maturation → recurrent PYOGENIC infections. DiGeorge: thymic/T-cell development. Severe combined: T AND B. |
| Secondary immunodeficiency | From disease, medications, malignancy or poor nutrition. |
| Age | Neonates: protected by maternal IgG and milk IgA, which wane. Older adults: weaker responses to NEW antigens; more autoantibodies. |
| Term | What you need to know |
|---|---|
| Hypoxemia vs hypoxia | Hypoxemia = low BLOOD oxygen (PaO2, arterial oxygen tension; saturation). Hypoxia = low TISSUE oxygenation. |
| Acute respiratory failure | On room air: PaO2 < 60 mmHg · PaCO2 (arterial carbon dioxide tension) > 50 mmHg · pH < 7.30. |
| Hypoxic failure | Low oxygen, NORMAL or LOW carbon dioxide: V/Q (ventilation/perfusion) mismatch · SHUNT · decreased diffusion · alveolar hypoventilation · altitude. |
| Hypercapnic failure | Carbon dioxide not removed: low ventilation or rate · cannot signal (Guillain-Barré, cord injury) · DEAD SPACE (pulmonary embolism, low output) · more carbon dioxide made (fever, burns) · cannot sense it (drugs). |
| ★ Dead space vs shunt | Dead space = ventilation without perfusion. Shunt = perfusion without ventilation. |
| Pulmonary circulation | HIGH FLOW, LOW PRESSURE: 22/8–25/8 mmHg, mean 15. Pulmonary arteries carry DEOXYGENATED blood (★ names = direction, not oxygen). |
| Pulmonary hypertension | Mean pulmonary arterial pressure AT REST > 20 mmHg (normal mean ≈ 15). |
| Routes to it | More FLOW (left-to-right shunt, polycythemia) · more RESISTANCE (hypoxic vasoconstriction, EMBOLISM, fibrosis) · higher LEFT ATRIAL pressure (mitral stenosis). |
| Vessel changes | MEDIA thickens (more muscle), INTIMA fibroses. |
| Lung cancers | SQUAMOUS 20–30%, central, sputum cytology. ADENO 35–40% (largest), peripheral. LARGE CELL 5–10%, peripheral. SMALL CELL 15–20%, central, doubles in ~33 days, PARANEOPLASTIC. |
| Term | What you need to know |
|---|---|
| Obstructive disease | Increased airflow RESISTANCE: in the WALL (asthma, bronchitis) · LOST PARENCHYMA (emphysema) · in the LUMEN (bronchiectasis, cystic fibrosis, foreign body). |
| Test pattern | Low FEV1/FVC (forced expiratory volume in 1 second / forced vital capacity) = airflow limitation · high RESIDUAL VOLUME = incomplete emptying · low DLCO (diffusing capacity for carbon monoxide) = a separate gas-transfer question. |
| Asthma | REVERSIBLE obstruction + airway inflammation + HYPER-RESPONSIVENESS. |
| Allergic (extrinsic) | IgE on MAST CELLS → histamine, LEUKOTRIENES (slow-reacting substances of anaphylaxis), prostaglandins, bradykinins, eosinophil chemotactic factor, serotonin. |
| Non-allergic (intrinsic) | Exercise, stress, irritants, aspirin; NEGATIVE skin tests, NORMAL IgE; middle age; worse prognosis. |
| Asthma airway | Epithelium DENUDED → goblet cells · COLLAGEN under basement membrane · edema · mucus plugs · VAGAL → mucus + bronchoconstriction · REMODELING. |
| Acute bronchitis | Inflamed trachea/bronchi, mostly VIRAL; more mucus, lost cilia; lasting HYPERIRRITABILITY explains the lingering cough. |
| Chronic bronchitis (type B) | Productive cough > 3 months a year for 2+ years; smoking 90%; gland + GOBLET hypertrophy; cilia → SQUAMOUS; plugs → V/Q mismatch. BLUE BLOATER = cyanosis + right-heart edema. |
| Emphysema (type A) | Alveolar wall DESTRUCTION WITHOUT FIBROSIS. PROTEASES from neutrophils/macrophages; smoking inactivates ALPHA-1 ANTITRYPSIN. Lost RADIAL TRACTION → more resistance, less airflow; air trapped → BULLAE. PINK PUFFER. |
| Emphysema types | CENTRIACINAR: respiratory bronchioles (with chronic bronchitis). PANACINAR: alveoli. PARASEPTAL: peripheral lobules. |
| Bronchiectasis | Wall DESTRUCTION → DILATED bronchi; congenital (50% related to cystic fibrosis) or acquired; children at risk (soft bronchi). Dilations = infection POCKETS → foul purulent sputum. Shapes: cylindrical, saccular, fusiform. |
| Cor pulmonale | Hypoxia → pulmonary VASOCONSTRICTION → pulmonary hypertension → RIGHT VENTRICULAR DILATION → right heart failure. |
| Term | What you need to know |
|---|---|
| Restrictive = expansion | DECREASED EXPANSION from parenchyma, pleura, chest wall or neuromuscular disease. LOW TOTAL LUNG CAPACITY confirms it (low FVC alone does not). |
| Interstitial lung disease | Starts with INJURY to alveolar epithelium or capillary endothelium → immune reaction → thick interstitium, COLLAGEN. |
| 3 alveolar patterns | INFLAMMATION (early, REVERSIBLE) → FIBROSIS (fibroblasts, collagen) → DESTRUCTION (end stage: STIFF, NONCOMPLIANT lungs). |
| Sarcoidosis | ALVEOLAR MACROPHAGES activated by an unknown trigger; NONCASEATING epithelioid GRANULOMAS (lymph nodes, lung); ASTEROID BODIES; abnormal T cells. |
| Hypersensitivity pneumonitis | Inhaled ORGANIC agents (birds, fungi, wheat weevil); antibodies → TYPE III immune complexes (cell-mediated immunity also contributes); nonsmokers. 'Extrinsic allergic alveolitis'. |
| Pneumoconiosis | Inhaled INORGANIC dust (coal, silica, asbestos); macrophages cannot clear it → FIBROSIS. Smoking depresses ciliary clearance. |
| ARDS (acute respiratory distress syndrome) | ATELECTATIC disorder. Alveolar-capillary membrane DAMAGE → LEAKY capillaries → protein-rich NONCARDIOGENIC edema; complement + neutrophil sequestration. |
| ARDS: 3 processes | Noncardiogenic EDEMA (leaky capillaries) · ATELECTASIS (no SURFACTANT) · HYALINE MEMBRANES (protein deposits). |
| Pulmonary edema (gathered) | Starling: hydrostatic OUT vs oncotic IN. More capillary pressure or less oncotic pressure → more filtration. Leaky capillaries → noncardiogenic edema. |
| Term | What you need to know |
|---|---|
| Primary pneumothorax | TALL, THIN MEN 20–40; SUBPLEURAL BLEBS at the apices rupture; smoking raises risk. |
| Secondary pneumothorax | Complication of lung disease: asthma, emphysema, cystic fibrosis, pneumonia, tuberculosis. |
| Tension pneumothorax | Pneumothorax that TRAPS AIR and builds pressure (penetrating or nonpenetrating injury); air ENTERS but cannot LEAVE → lung collapses, mediastinum shifts AWAY → less VENOUS RETURN and CARDIAC OUTPUT. |
| Pleural effusion causes | Raised HYDROSTATIC pressure (heart failure) · lowered ONCOTIC pressure (nephrotic syndrome, cirrhosis) · lowered pleural pressure (lung collapse). Normal 5–15 mL. |
| Transudate | Protein ratio < 0.5 · LDH (lactate dehydrogenase) ratio < 0.6 · specific gravity < 1.016. PRESSURE problem: heart failure, cirrhosis, nephrotic syndrome. |
| Exudate | Protein ratio > 0.5 or LDH ratio > 0.6 (ONE criterion is enough). PERMEABILITY or LYMPHATIC problem: cancer, infection, PULMONARY EMBOLISM, sarcoidosis. |
| Chylothorax | CHYLE leaking from the THORACIC DUCT (trauma, lymphoma). |
| Obstructive sleep apnea | ≥ 5 events/hour; collapsible PHARYNX closes. APNEA: no airflow ≥ 10 s WITH effort. HYPOPNEA: reduced flow + desaturation or arousal. No flow + NO effort = CENTRAL. |
| Pneumonia sources | ASPIRATION (gross aspiration → ANAEROBES, abscess) · inhalation (virus, Mycoplasma) · BLOOD-BORNE (right-sided endocarditis, intravenous drug use). |
| Community vs hospital | Community: at home, or hospitalized < 48 h. Hospital: early (≤ 4 days) susceptible bacteria; LATE = MULTIDRUG-RESISTANT. |
| Pulmonary embolism (gathered) | Raises DEAD SPACE (hypercapnia) · causes pulmonary hypertension by OBSTRUCTION · causes ARDS and acute respiratory failure · EXUDATIVE effusion. |
| Grade | Absolute neutrophil count |
|---|---|
| Mild | 1,000–1,500 cells/µL |
| Moderate | 500–1,000 cells/µL |
| Severe | < 500 cells/µL |
| Agranulocytosis | < 200 cells/µL |
| ★ The only lab values the lecturer said to memorize. | |
“Fifteen, ten, five, two” — hundreds per microliter, counting down.
15 below 1,500 = mild10 below 1,000 = moderate5 below 500 = severe2 below 200 = agranulocytosis
| Group | Process | Members / note |
|---|---|---|
| Myelodysplastic (MDS) | Ineffective hematopoiesis with cytopenias and DYSPLASIA | Can progress to AML |
| Acute myeloid leukemia (AML) | Impaired DIFFERENTIATION + abnormal BLAST proliferation | Distinct from MDS |
| Myeloproliferative (MPN) | CLONAL PROLIFERATION of myeloid cells | CML · polycythemia vera · essential thrombocythemia · primary myelofibrosis (can cause cytopenias) |
Dys-, blasts, pro-: made badly, never grow up, made too many.
Dys myelodysplasticBlasts acute myeloid leukemiaPro myeloproliferative
Where it breaks: MPN members by first letters: “Can People Eat Pie?” = CML, Polycythemia vera, Essential thrombocythemia, Primary myelofibrosis.
| Cell of origin | Neoplasm | Word |
|---|---|---|
| Precursor B or T cells | Acute lymphoblastic leukemia/lymphoma | PRECURSOR |
| Mature B cells | Chronic lymphocytic leukemia / small lymphocytic lymphoma and other B-cell lymphomas | MATURE |
| Mature T and NK cells | Distinct T-cell and NK-cell neoplasms | MATURE |
| Germinal-center B cells | Classic Hodgkin lymphoma | — |
| Differentiated antibody-producing B-lineage cells | Plasma-cell myeloma | DIFFERENTIATED |
A-C-M runs young to old: Acute (precursor) → Chronic (mature) → Myeloma (differentiated).
A acute lymphoblastic — precursorC chronic lymphocytic — matureM myeloma — differentiated
Where it breaks: Hodgkin lymphoma (germinal-center B cells) and the mature T/NK neoplasms sit outside the chain.
| Group | MCV | Causes on the slide |
|---|---|---|
| Microcytic | < 80 fL | Iron deficiency · thalassemia · inflammation (some cases) · sideroblastic anemia |
| Normocytic | 80–100 fL | Blood loss or hemolysis · inflammation or renal disease · marrow failure or infiltration · EARLY iron deficiency |
| Macrocytic | > 100 fL | Megaloblastic: B12 or folate deficiency · Nonmegaloblastic: liver disease, alcohol, drugs, reticulocytosis |
| Marrow response (reticulocytes / RPI): LOW = reduced production, or an early/blunted response to loss or destruction · INCREASED = blood loss, hemolysis or recovery; a rise usually takes several days. | ||
Micro “TICS”: Thalassemia, Iron deficiency, Chronic inflammation, Sideroblastic.
T thalassemiaI iron deficiencyC inflammation (some cases)S sideroblastic
Where it breaks: The C is a memory addition (“chronic”); the slide says inflammation (some cases).
| Type | Red-cell mass | Mechanism |
|---|---|---|
| Relative | Not increased | Reduced PLASMA volume (dehydration) |
| Absolute — polycythemia vera | Increased | Clonal myeloproliferative neoplasm |
| Absolute — secondary | Increased | Erythropoietic response to hypoxia, increased erythropoietin or other stimuli |
Water, clone, or air: plasma lost, a clone, or hypoxia.
Water relativeClone polycythemia veraAir secondary (hypoxia)
Where it breaks: Secondary also includes increased erythropoietin and other stimuli.
| Item | Factors / cause |
|---|---|
| PT (prothrombin time) | Extrinsic VII + common |
| aPTT (activated partial thromboplastin time) | Intrinsic XII, XI, IX, VIII + common |
| Common pathway | X, V, II, I |
| Hemophilia A | Factor VIII deficiency |
| Hemophilia B | Factor IX deficiency |
| Von Willebrand disease | VWF supports platelet adhesion and carries/stabilizes factor VIII |
| Factor V Leiden (thrombophilia) | Genetic mutation |
| Antiphospholipid syndrome (thrombophilia) | Autoimmune response |
Common pathway = “10, 5, 2, 1” — like a countdown to the clot. PT has the one short factor (VII); PTT the long list (12, 11, 9, 8).
A→8 hemophilia A = VIIIB→9 hemophilia B = IX
Where it breaks: Covers the common pathway, the two tests and the hemophilias only; von Willebrand disease, factor V Leiden and antiphospholipid syndrome are not in the aid.
| Term | What you need to know |
|---|---|
| Blood | 55% PLASMA, 45% formed elements; plasma 90–92% water; SERUM = fluid left after clotting. Adult hematopoiesis: AXIAL skeleton + PROXIMAL humerus and femur. |
| Lineage | MYELOID progenitor → erythroid precursors, MEGAKARYOCYTES (platelets), granulocytes, monocytes (→ MACROPHAGES). LYMPHOID → B, T, NK cells. |
| Normal differential | Neutrophils 40–60% · lymphocytes 20–40% · monocytes 2–8% · eosinophils 1–4% · basophils 0.5–1%. |
| Relative vs absolute | Absolute = WBC count × relative fraction. A fall in one type can ARTIFICIALLY raise another's percentage. |
| Neutrophils | First responders; with macrophages, the PHAGOCYTIC leukocytes. Neutrophilia → acute BACTERIAL inflammation. Severe neutropenia → serious infection risk. |
| Bands | BANDEMIA = more immature neutrophils (LEFT SHIFT). Historical SIRS: > 10% bands. SEPSIS-3 = infection-associated, life-threatening ORGAN DYSFUNCTION. |
| Monocytes ↑ | Chronic myelomonocytic leukemia · autoimmune (sometimes) · chronic infection (CMV, tuberculosis). |
| Eosinophils ↑ | ALLERGY (esp. asthma) · PARASITE · DRUG effect; rarely neoplastic/autoimmune. |
| Basophils ↑ | Bind IgE; parasites and allergy; few on a CBC → consider MALIGNANCY. |
| V(D)J | B cells rearrange immunoglobulin genes in the MARROW: heavy chains V, D, J; LIGHT chains V and J. Germinal centers: SOMATIC HYPERMUTATION → affinity maturation. |
| Clonality | Clone = descended from ONE progenitor. PCR finds a dominant receptor-gene rearrangement, but REACTIVE or premalignant cells can be clonal too → not proof of malignancy. |
| Acute leukemia | ★ MATURATION ARREST (transcription-factor mutations) + growth factor–independent proliferation → LYMPHOBLASTS / MYELOBLASTS. |
| Leukemia counts | Peripheral WBC LOW, NORMAL or HIGH; marrow involvement suppresses normal production → CYTOPENIAS. Hyperleukocytosis = very high count; LEUKOSTASIS = impaired microcirculation + organ injury (LUNGS, BRAIN). |
| Risk factors | Chemical, viral, radiation MUTAGENS (effects of chemotherapy or immunodeficiency disorders). Result: too few normal WBC, RBC, platelets. |
| Lineage figure | Red-cell line → POLYCYTHEMIA VERA / erythroid leukemia; megakaryocyte → ESSENTIAL THROMBOCYTHEMIA / megakaryocytic leukemia. |
| Multiple myeloma | CLONAL PLASMA CELLS in marrow. Proteins + infiltration → RENAL injury, ANEMIA, impaired IMMUNITY; altered bone remodeling → OSTEOLYTIC lesions + HYPERCALCEMIA. Active = plasma-cell neoplasm + a MYELOMA-DEFINING EVENT (bone lesions not required). |
| Term | What you need to know |
|---|---|
| Indices | MCV = average VOLUME · MCH = average hemoglobin MASS per cell · MCHC = hemoglobin CONCENTRATION in packed cells. |
| Morphology clues | SIZE · HEMOGLOBINIZATION (color: normo-/HYPOCHROMIC) · SHAPE. |
| Small vs big | Microcytic hypochromic = HEMOGLOBIN SYNTHESIS disorder. Macrocytic = impaired ERYTHROID PRECURSOR MATURATION. Normocytic: SHAPE is the clue. |
| Anemia | Reduces OXYGEN-CARRYING capacity; defined by HEMOGLOBIN below the cutoff for age, sex, pregnancy. WHO 2024 (15–65): < 13 g/dL men, < 12 g/dL nonpregnant women. Read Hb/Hct against PLASMA volume. |
| Hemolysis | Survival < ~120 DAYS; breakdown products ↑; EPO and reticulocytes ↑ if marrow compensates; blunted by marrow disease, nutrient deficiency, RENAL disease, infection. |
| Extravascular | Old red cells die in MACROPHAGES (spleen, liver, marrow) — age-dependent SURFACE PROTEIN changes. Most hemolytic anemias: premature destruction in PHAGOCYTES = EXTRAVASCULAR. |
| Hereditary spherocytosis | Lose lipid MEMBRANE → RIGID spherocytes → TRAPPED in spleen → eaten by splenic macrophages. |
| Diminished erythropoiesis | Megaloblastic · vitamin B12 deficiency · IRON deficiency · APLASTIC anemia. |
| Initiation | ★ TISSUE FACTOR–VIIa activates IX and X; external bleeding NOT required. |
| Key reactions | ★ IXa + VIIIa → Xa · Xa + Va → THROMBIN (from prothrombin) · thrombin: fibrinogen → fibrin · XIIIa crosslinks. COFACTORS = VIIIa and Va; Ca²⁺ + phospholipid assemble complexes. |
| Regulation vs fibrinolysis | LIMIT coagulation: ANTITHROMBIN + activated PROTEIN C with PROTEIN S. Fibrinolysis (separate): plasminogen → PLASMIN degrades fibrin. |
| Thrombocytopenia | Reduced marrow production · IMMUNE destruction (ITP) · drug reactions (immune HIT). |
| Thrombocytosis | REACTIVE: inflammation, infection, IRON deficiency · PRIMARY: clonal marrow disorder. |
| Qualitative platelet | Inherited: ADHESION, AGGREGATION, SECRETION · Acquired: external factors, systemic disease. |
| HIT | Immune heparin-induced thrombocytopenia: platelet ACTIVATION → THROMBOSIS despite a falling count. |